Allogene Therapeutics, Inc. (ALLO)
Biological Products, (No Diagnostic Substances)
Latest Price
$1.78
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
1.53
P/B Ratio
1.16
Institutional Ownership
91.0% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 30.15M | $62.0M | 8.73% | +11.06M | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 22.45M | $46.0M | 6.50% | +18.65M | 2026-06-30 |
| Pfizer Inc | 22.03M | $46.0M | 6.38% | -- | 2026-06-30 |
| STATE STREET CORP | 19.03M | $39.0M | 5.51% | +10.37M | 2026-06-30 |
| TPG GP A, LLC | 18.72M | $38.0M | 5.42% | -- | 2026-06-30 |
| Sio Capital Management, LLC | 13.32M | $27.0M | 3.86% | -- | 2026-06-30 |
| PRIMECAP MANAGEMENT CO/CA/ | 13.12M | $27.0M | 3.80% | +4.74M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 12.17M | $25.0M | 3.52% | +5.25M | 2026-06-30 |
| FMR LLC | 12.01M | $24.0M | 3.48% | +10.42M | 2026-06-30 |
| CITADEL ADVISORS LLC | 10.22M | $21.0M | 2.96% | +3.34M | 2026-06-30 |